Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial
September 28, 2015 at 08:02 AM EDT
A Phase II study of Eli Lilly and Company's (NYSE: LLY) CYRAMZA® (ramucirumab) in combination with docetaxel met its primary endpoint, ...
